+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global HIV Therapeutic & Preventive Vaccines Market - Segmented by Type and Geography 2017 - 2022

  • ID: 4388367
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
HIV/AIDS has become one of the leading infectious diseases which is taking a huge death toll across the globe, surpassing malaria and TB. There were about 35.3 million people currently living with HIV. In recent years there have been significant developments achieved in terms of prevention and treatment of HIV/AIDS. The HIV vaccines market is expected to grow modestly from $XX million in 2014 to $XX million in 2020, at a CAGR of XX%.

The Global HIV Therapeutic & Preventive Vaccines Market is discussed under two parts namely the Therapeutic vaccines and the Preventive vaccines. In addition, the HIV vaccines are also classified under various phases of research like Preclinical, Clinical, Phase I, II, III, IV etc. Furthermore, based on geography it is segmented under Asia-Pacific, North America Europe and Latin America regions.

Irrespective of whether the country is developed or not, the disease is becoming more prevalent, with serious impact in the developing countries. It has been witnessed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, of which nearly two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number compared to any country in the world. In spite of the combating efforts, the Asian and other emerging regions are increasingly witnessing the heat as HIV continues to spread at a significant rate.

Some of the key participants in the industry include Antigen Express, Bionor Pharmaceuticals, Celldex Therapeutics, Glaxo Smith Kline, Inovio Pharmaceuticals, Novartis, Profectus Biosciences, Sanofi, GeneCure


The large number of unmet needs related to the disease is attracting many multi-national companies to invest in this division. And also the increasing health care expenditure, technological developments & drug innovations with regard to HIV and growing concern across the world are expected to fuel the growth of the market further.


The low success rate in clinical trials for therapeutics, high costs and complexity associated with the research studies limits the growth of the market.

Key Deliverables in the Study?

Market Definition for the Global HIV Therapeutic & Preventive Vaccines Market along with identification of key drivers and restraints for the market.
Market analysis for the Global HIV Therapeutic & Preventive Vaccines Market, with region specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the Macro and Micro factors that affect the HIV Therapeutic & Preventive Vaccines Market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 3
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Applications of Industrial Internet of Things
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value-Chain Analysis
5.6 Product Life-Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter’s Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat of New Entrants
5.9.4 Threat of Substitute Products and Services
5.9.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Incresing prevelance of the disease in all the regions
6.1.2 Increase in R&D expenditures of Pharmaceutical companies
6.1.3 Increasing concern across the globe
6.2 Market Restraints
6.2.1 Low success rate in clinical trails for HIV vaccines
6.2.2 High costs and complexity associated with the research
6.3 Key Challenges
6.4 Current Opportunities in the Market
7. Global Therapeutic HIV Vaccines Market
8. Global Preventive HIV Vaccines Market
8.1 Subunit vaccines
8.2 Recombinant vector vaccines
8.3 DNA vaccines
9. Global Therapeutic & Preventive HIV Vaccines Market, By Region
9.1 North America
9.1.1 Introduction
9.1.2 United States
9.1.3 Canada
9.1.4 Rest of North America
9.2 Europe
9.2.1 Introduction
9.2.2 Germany
9.2.3 France
9.2.4 Spain
9.2.5 Italy
9.2.6 U.K.
9.2.7 Rest Of Europe
9.3 Asia-Pacific
9.3.1 Introduction
9.3.2 China
9.3.3 India
9.3.4 Japan
9.3.5 South Korea
9.3.6 Australia
9.3.7 Rest of Asia-Pacific
9.4 Latin America
9.4.1 Introduction
9.4.2 Brazil
9.4.3 Argentina
9.4.4 Mexico
9.4.5 Rest of Latin America
9.5 Middle East & Africa
9.5.1 Introduction
9.5.2 Saudi Arabia
9.5.3 UAE
9.5.4 Israel
9.5.5 Rest of MEA
10.Global HIV Therapeutic & Preventive Vaccines Market, by Phase
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase I
10.5 Phase II
10.6 Phase III
10.7 Phase IV
11. Competitive Landscape
11.1 Merger and Acquisition Analysis
11.2 Patent Analysis
11.3 The Challengers
12.Key Vendor Analysis
12.1 Antigen Express
12.2 Bionor Pharmaceuticals
12.3 Celldex Therapeutics
12.4 Glaxo Smithkline
12.5 Inovio Pharmaceuticals
12.6 Novartis
12.7 Profectus Biosciences
12.8 Sanofi
12.9 GeneCure
12.10 Argo Therapeutics
13. Analyst Outlook for Investment Opportunities
14. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3